FO.NE.SA. ONLUS Foundation (Fondazione Neoplasie Sangue) is born in the July of 2004 in Torino at the “Molinette” Medical Center. The primary aim has been to create a non-profit organization involved in the financial, economic, operative and administrative support to the activities of scientific research on hematologic disorders, with close attention to multiple myeloma.

Over the last years, FO.NE.SA. fostered and promoted many projects and followed and helped financially many patients and families affected by relevant economic difficulties, along their path of recovery and support to the sick relative.

Always active and purposeful, FO.NE.SA. functionally participated in European and global cooperative groups, encouraging exchanges of information and data among researchers and scientists.

Among the main activities of FO.NE.SA., we can count new protocols for patients; the availability of last-generation drugs not yet obtainable in Italy but already approved by distinguished trials; and scientific publications, articles, posters, and meeting presentations. Moreover, there is also the Data Center, where clinical data regarding patients affected by malignant hematologic disorders are collected and processed, in order to ensure fairness, accuracy, and conformance with the experimental protocols.

Scientific research is also all this; not merely studies and laboratory trials, but also data management and clinical case analysis, reports and information exchanges among centers and study groups, and a monitored and verified pharmaceutical experimentation. Patients and their relatives know this very well, and over the years they always supported FO.NE.SA. and its activities.

Multiple myeloma explained in short

Multiple myeloma is a form of cancer affecting plasma cells, which are essential for the functioning of the immune defense system. This pathology accounts for approximately 1% of cancer disorders and 13% of hematologic cancers. In Western countries the annual incidence is 5,6 cases per 100.000 inhabitants. The median age at diagnosis is approximately 70 years and the incidence grows considerably with age: 37% of patients are younger than 65 years, 26% are between the ages of 65 and 74 years, and 37% are 75 years of age or older. 

Plasma cells originate mainly in the bone marrow, producing and secreting antibodies to neutralize infections. However, sometimes their growth proliferates uncontrollably originating the tumor.

The abnormal proliferation of plasma cells may become problematic for other blood cells (red blood cells, white blood cells and platelets), inducing the weakening of immune defenses, anemia, and defective coagulation. Moreover, other dysfunctions may occur, such as renal insufficiency, bony lesions and hypercalcemia.

Over the last 20 years we have seen great advances in the treatment of myeloma, thanks to the introduction of peripheral stem-cell autologous transplantation and, more recently, of novel drugs. Further steps forward will be possible thanks to the clinical research.

Useful Links



This website uses cookies to improve your browsing experience. By continuing to browse this website, you agree to our use of cookies. Read the privacy policy